WO2008010527A1

WO2008010527A1 - Composition for amelioration of defecation

Info

Publication number: WO2008010527A1
Application number: PCT/JP2007/064205
Authority: WO
Inventors: Shinji Somekawa; Mio Fujimaki; Naoki Hayashi
Original assignee: Ajinomoto Co., Inc.
Priority date: 2006-07-18
Filing date: 2007-07-18
Publication date: 2008-01-24
Also published as: JP5412830B2; JPWO2008010527A1

Abstract

Disclosed is a composition for ameliorating defecation more effectively. Specifically disclosed is a composition for ameliorating defecation, which comprises at least one member selected from the group consisting of glutamic acid, a derivative thereof and a 5'-nucleotide.

Description

Specification

Composition for improving bowel movement

Technical field

[0001] The present invention relates to a composition effective for preventing or improving bowel movement abnormalities. The composition is used as a medicine or food.

Background art

[0002] With the aging of the population rapidly accelerating, gastrointestinal motility declines with increasing age, and so many elderly people suffer from bowel movement abnormalities. This is a major burden on the person and the caregiver.

[0003] Furthermore, with the increase in diseases such as cerebrovascular disorders, an increasing number of patients are unable to replenish with nutrients and various water-soluble drugs orally. ing. This gastrostomy's enteral tube feeding method uses liquid nutrients via a tube that is surgically or endoscopically constructed in the esophagus, stomach, or jejunum and placed in place. This is a method of intermittent injection that can supply nutrients directly to the stomach and intestines. Therefore, it is said that nutrition can be fed through the digestive tract as well as healthy people, and the quality of life (hereinafter referred to as QOL) of patients can be improved. Even when liquid nutrients are administered to patients by gastrostomy and enteral tube feeding, there is a risk of inducing symptoms such as constipation, that is, abnormal bowel movements.

[0004] On the other hand, high-viscosity and / or aqueous solutions and nutrients may be used for the purpose of preventing aspiration diarrhea, but this may make bowel movement abnormal due to the extension of gastric stagnation time due to increased liquid viscosity It is reported that constipation worsens (Non-patent Document 1).

[0005] As functional foods showing the effect of promoting defecation, indigestible food fibers having an intestinal regulating action, foods containing oligosaccharides which are bifido factors, and the like are known. However, there are many cases in which defecation disorder is not improved or difficult to take depending on these foods. Non-patent document 1: Jiro Kanie, “Nursing of gastrostomy PEG complications and practice of solidified nutrition” 2004, 125-132, 162-163 Disclosure of the invention

Problems to be solved by the invention

[0006] An object of the present invention is to provide a composition effective in preventing or improving bowel movement abnormalities.

Means for solving the problem

[0007] The present inventors have found that glutamic acid or a derivative thereof, or 5′-nucleotide has an effect of improving abnormal bowel movement, and have completed the present invention.

That is, the present invention provides the following.

[1] A composition for improving bowel movement comprising at least one member selected from the group consisting of glutamic acid and derivatives thereof, and 5′-nucleotide.

[2] glutamic acid, a derivative or 5'the content of nucleotides free glutamic acid or a 0. 05-2. 0 wt ^_0/0 as the free 5'-nucleotide, [1] composition.

[3] Viscosity at 25 ° is in the range of 40011 1½ '3-10, OOOmPa's, [1] or [2

] The composition as described.

[4] The composition according to any one of [1] to [3], which is used in combination with a nutrient.

[5] The composition according to any one of [1] to [3] for use in combination with a nutrient.

[6] The composition according to [4] or [5], wherein the nutrient is a transesophageal, gastric, or enteral nutrient

Yes

[7] The composition according to any one of [1] to [3], wherein the composition is used in combination with a high-viscosity composition having a viscosity at 25 ° C of 400 mPa's to 10 and OOO mPa's. .

[8] The composition according to any one of [1] to [3], for use in combination with a high-viscosity composition having a viscosity at 25 ° C of 400 mPa's to 10 and OOO mPa's.

[9] The composition according to any one of [1] to [8], which is a pharmaceutical product.

[10] The composition according to any one of [1] to [8], which is a food or drink.

[11] Dose power S of glutamic acid, derivative thereof or 5′-nucleotide, daily free glutamic acid or free 5′-nucleotide as 0.0;! To 20 g, composition according to [9] or [10] .

[12] The group according to [10], wherein the food or drink is a health functional food or a dietary supplement Adult.

[13] The composition according to [12], wherein the functional health food is a food for specified health use or a functional food for nutrition.

[14] An indication that it contains at least one member selected from the group consisting of glutamic acid and derivatives thereof, and 5 ′ nucleotide, has an effect of improving bowel movement, and is used for improving bowel movement Foods marked with

[15] The food according to [14], wherein the food is a health functional food or a dietary supplement. [16] The food according to [15], wherein the health functional food is a food for specified health use or a nutritional functional food

P

P o

[17] A method for preventing or improving bowel movement abnormalities, comprising containing at least one member selected from the group consisting of glutamic acid and derivatives thereof, and 5′-nucleotide as an active ingredient, and administering an effective amount thereof to a subject.

[18] The method according to [17], wherein the effective amount of the active ingredient is 0.05-2.0% by weight as free glutamic acid or free 5 ′ nucleotides.

[19] The method according to [17] or [18], wherein the active ingredient is administered as a composition having a viscosity in the range of 400 mPa's to 10, OOOmPa's.

[20] The method according to any one of [17] to [; 19], wherein the active ingredient is administered in combination with a nutrient.

[21] The method according to [20], wherein the nutrient is a transesophageal, gastric or enteral nutrient. [22] A combination of an active ingredient and a high viscosity composition in the range of 10, OOOmPa's at 25 ° C, [17] to [; 19] The method in any one of. [23] Use of at least one active ingredient selected from the group consisting of glutamic acid and derivatives thereof and 5 ′ nucleotides for the production of a composition for improving bowel movement.

[24] The use according to [23], wherein the content of glutamic acid, a derivative thereof or 5 ′ nucleotide in the composition for improving bowel movement is 0.05-2.0% by weight as free glutamic acid or free 5 ′ nucleotide.

[25] Use according to [23] [24], wherein the viscosity of the composition for improving bowel movement is in the range of 400 mPa's to 10, OOOmPa's. [26] The use according to any one of [23] or [24], wherein glutamic acid, a derivative thereof or 5′-nucleotide and a nutrient are used in combination.

[27] The use according to any one of [23] or [24], wherein the composition for improving bowel movement is used in combination with a nutrient.

[28] The use according to [26] or [27], wherein the nutrient is a transesophageal, gastric or enteral nutrient.

[29] The composition for improving bowel movement is used in combination with a high-viscosity composition in the range of 10, OOmPa · s at 25 ° C; ] Use according to any one of the above.

[30] A commercial package containing a glutamic acid and a derivative thereof, a content including at least one selected from the group consisting of 5′-nucleotides, and a description including a description regarding use for the purpose of improving bowel movement.

[31] The commercial package according to [30], which relates to a medicine.

[32] The commercial package according to [30], which relates to food.

[33] A bowel movement improving agent comprising at least one member selected from the group consisting of glutamic acid and derivatives thereof, and 5′-nucleotide.

The invention's effect

[0008] The composition for improving bowel movements of the present invention is effective in preventing or improving excellent bowel movement abnormalities. In particular, it is useful for improving bowel movement caused by transesophageal, gastric or enteral nutrition. Furthermore, since the composition of the present invention contains at least one member selected from the group consisting of glutamic acid and its derivatives and 5′-nucleotide as an active ingredient, it has very little harmful reaction. In particular, it has the advantage that it does not cause rapid constipation, abdominal pain, diarrhea, etc. as seen when taking laxatives.

Brief Description of Drawings

[0009] FIG. 1 is a graph showing the proportion of defecation accumulated for each individual.

FIG. 2 is a graph showing the proportion of individuals who defecate.

BEST MODE FOR CARRYING OUT THE INVENTION

[0010] The present invention is a group consisting of glutamic acid and derivatives thereof, and 5'-nucleotide. A composition for improving bowel movements comprising at least one selected from the group consisting of:

In the present invention, “improvement of bowel movement” means prevention of onset of abnormal bowel movement or improvement of abnormal bowel movement (for example, prevention or improvement of bowel movement), for example, without causing diarrhea (that is, normal bowel movement or In a loose stool state), preferably refers to regular stable defecation. Therefore, “improvement of bowel movement” in the present invention includes prevention of abnormal bowel movement.

In the present invention, the bowel movement abnormality is caused by the following causes, for example.

(1) Constipation that occurs when gastrostomy / enteral tube feeding method is applied by injecting liquid nutrients into the digestive tract via a tube placed with an external fistula (fistula) in the esophagus, stomach, or jejunum .

(2) Constipation that occurs due to an increase in gastric stagnation time due to an increase in the viscosity of the gastrointestinal contents when a highly viscous aqueous solution and / or nutrient is ingested.

[0012] In the present invention, glutamic acid can be any of L-integral, D-isomer, and DL-isomer, preferably L-integral and DL-isomer, and more preferably L-integral. In the present invention, any of these cases is included in the present invention. In addition, glutamic acid is a concept including salts thereof, and embodiments of the salts are also included in the present invention. In this specification, these are collectively referred to as “glutamic acid”!

[0013] In the present invention, the derivative of glutamic acid may be glutamic acid as long as it is capable of exhibiting the desired effect of the present invention as glutamic acid by in vivo metabolism, for example, by hydrolysis in vivo. It is a concept that includes a salt as well. Examples thereof include dipeptides and tripeptides containing glutamic acid, and polymers containing glutamic acid as a main component. Examples of such derivatives are as follows.

Alanylglutamine, arginine glutamate, poly-γ-glutamic acid, lysine gnoretamine, and calcium glutamate.

In the present invention, 5 ′ nucleotides include 5 ′ inosinic acid, 5′-guanylic acid, 5′-adenylic acid, 5′-cytidylic acid, 5′-uridylic acid, and 5′-xanthylic acid, Of these, 5'-inosinic acid and 5'-guanylic acid are preferred. In the present invention, any of these cases is included in the present invention. And 5'-nucleotide is The concept includes salts thereof, and embodiments of the salts are also included in the present invention. In the present specification, these are collectively referred to as “5′-nucleotide”! /.

[0015] As described above, the present invention also includes glutamic acid or a derivative thereof, or a salt of 5'-nucleotide, and the term "salt" refers to a salt with an inorganic base and a salt with an organic acid. Can be mentioned. Examples of the salt with an inorganic base include alkali metal salts such as sodium, potassium and lithium, alkaline earth metal salts such as calcium and magnesium, and ammonium salts. Examples of the salt with inorganic acid include salts with hydrohalic acid (hydrochloric acid, hydrobromic acid, hydroiodic acid, etc.), sulfuric acid, nitric acid, phosphoric acid and the like. Examples of the salt with organic acid include salts with formic acid, acetic acid, propionic acid, oxalic acid, succinic acid, maleic acid, fumaric acid, citrate, glutamic acid, aspartic acid, histidine and the like. Of these, alkali metal salts such as sodium salts are preferred.

[0016] The content of glutamic acid or a derivative thereof when the composition of the present invention is used in combination with a nutrient, particularly by incorporating the nutrients described below (for example, transesophageal, gastric, and enteral nutrients) as free glutamic acid, preferably 0. 05-2 0 wt ^_0/0, more rather preferably is 0.;.! ~ 1. is 8 weight ^_0/0. Similarly, the content of 5,1 nucleotide is preferably 0.05-2.0% by weight, more preferably 0.;! ~ 1.8% by weight as free 5,1 nucleotide. The weight% of the glutamic acid derivative is the amount of free glutamic acid produced by hydrolyzing the derivative. If the content is within this numerical range, an excellent bowel movement improving effect that causes an adverse reaction can be exhibited.

[0017] The composition of the present invention is useful as a medicine, food and drink, etc. The administration target thereof is a mammal (eg, human, mouse, rat, mouse, muster, usagi, cat, inu, ushi, Higgies and monkeys). When applied to mammals other than humans, the dose (intake) of the composition may be appropriately adjusted according to the body weight or size of the animal.

[0018] The administration form of the composition of the present invention is not particularly limited, but general administration such as oral administration, transesophageal administration, gastric administration, or enteral administration (enteral administration, rectal administration, or jejunal administration), etc. You can go through the route. The dosage form includes general pharmaceutical preparations such as tablets (eg, sugar-coated tablets and film-coated tablets), pills, capsules, sachets, suspensions, solutions, syrups, gam preparations, drops preparations and powders. The mold can be adopted The The composition of the present invention is preferably used in combination with a nutrient because it suppresses constipation that occurs during enteral administration, for example. At that time, for example, enteral administration or the like is performed as a preparation mixed with the nutrient or as a preparation separate from the nutrient. In addition, the composition of the present invention suppresses constipation or the like that occurs during high-viscosity compositions (such as high-viscosity aqueous solutions and high-viscosity nutrients), for example, during enteral administration. It is preferable to use together with the product. At that time, it is preferable to carry out enteral administration, for example, as a preparation blended with a high-viscosity composition or as a preparation separate from the high-viscosity composition. In the above, enteral administration has been described, but the same applies to oral and gastric administration.

[0019] Preparation of the preparation is carried out by formulating it by a conventional method. In the formulation, various pharmacologically acceptable pharmaceutical substances can be added as necessary. The substance for the preparation can be appropriately selected depending on the dosage form of the preparation. For example, the excipient, the diluent, the disintegrant, the binder, the coating agent, the lubricant, the lubricant, the lubricant, the flavor, and the sweetener. , Solubilizers, thickeners and the like. Furthermore, specific examples of pharmaceutical substances include magnesium carbonate, titanium dioxide, ratatoose, mannitol and other sugars, talc, milk protein, gelatin, starch, cellulose and its derivatives, animal and vegetable oils, polyethylene glycol, and solvents. For example, sterilized water and mono- or polyhydric alcohols such as glycerol.

Examples of the form of the composition of the present invention include solid, powder, liquid, and semisolid. For tube feeding, a liquid or semi-solid form is preferred.

[0020] The content of glutamic acid or a derivative thereof or 5'-nucleotide in the preparation is preferably 0.01 g to 20 g as a free gnoretamic acid and 0.01 g to 20 g as a free 5'-nucleotide.

[0021] When the composition for improving bowel movements of the present invention is used as a pharmaceutical, the dose varies depending on the age, weight or disease state, dosage form, or administration method of the subject patient. Daily dosages of glutamic acid or its derivatives, or 5'-nucleotide are generally 0.01 g to 20 g as free glutamic acid and 0.01 g to 20 g as free 5'-nucleotide. In the case of general adults, it is preferable that the daily dose of dartamic acid or a derivative thereof, or 5′-nucleotide, be adjusted with free glutamic acid. Then, 0.01 g to 20 g, more preferably 0.1 lg to;! Og, and the free 5, single nucleotide is 0.01 g to 20 g. The daily dose can be administered at once or in several divided doses (eg 3 times). The timing of administration does not matter before meals, after meals, and between meals. The administration period is not particularly limited.

[0022] The composition for improving bowel movements of the present invention may be administered alone, or may be administered in combination with a nutrient such as a transesophageal nutrient, a gastric nutrient, and an enteral nutrient. . When administered in combination with a nutrient, it may be formulated in a nutrient or separately. When formulated separately, the route of administration and dosage form may be the same or different, and the timing of administration of each may be simultaneous or separate. Good. These matters are appropriately determined depending on the type of nutrient used in combination.

The transesophageal, gastro and enteral nutrients used in combination with the present invention are originally used for efficient nutritional supplementation, so the ingredients used are purified raw materials with very good digestion and absorption. The gastrointestinal tract has a low residue. Therefore, constipation occurs at a high rate in patients with inactive gastrointestinal motility, especially in the elderly, because there is no stool stimulation due to insufficient stool volume. This is a serious problem not only for patients but also for healthcare workers and caregivers. In this treatment, laxatives and bowel regulators are administered. By using the product of the present invention, it is possible to prevent abnormalities of defecation of these nutritional supplement users and to save the cost of laxatives and intestinal preparations.

[0023] The composition for improving bowel movements of the present invention can be used together with conventionally known nutrients that cause abnormal bowel movements. For example, the nutrient is a nutritional composition containing at least one nutrient of protein, carbohydrate, and lipid. More specifically, proteins (casein as animal protein, milk protein such as salt and whey, fish protein, egg protein, and soy protein, wheat protein, and corn protein as vegetable protein, etc.) Including raw materials processed into powder, granules, flakes or pellets), sugars (such as glucose and fructose), disaccharides (such as sucrose, lactose, and maltose), and polysaccharides (starch, As well as fat (animal fat or vegetable fat), various amino acids (excluding glutamic acid), vitamins (such as fat-soluble vitamins and water-soluble vitamins), and minerals (calcium, magnesium, etc.) Potassium, sub For example, lead or iron). From the viewpoint of energy supply and management, the composition of nutrients is protein, carbohydrate, and fat, but is not limited thereto.

In particular, stool abnormalities such as constipation are likely to occur in patients who have been administered high-protein, high-calorie nutrients for a long period of time. Here, the high calorie and high protein nutrient means a protein content of, for example, 5 to 15 mass%, particularly 7 to 14 mass%. Even when the calorific value is 1.5-2. 2 kcal / g, 40-50 g / day, which is the amount of protein required for elderly people over 70 years old, can be obtained only with the nutrient. In this case, at least milk protein or soybean protein is contained. If necessary, a hydrolyzate or amino acid of the protein raw material may be added to supplement the protein. These proteins or protein lysates and lysates can be present in various proportions. The above nutrient may be contained in the composition of the present invention.

[0024] When the composition for improving bowel movements of the present invention is used in combination with a nutrient, the dose of the active ingredient varies depending on the age, weight or pathological condition, dosage form, administration method, etc. of the subject patient. As a guideline, the daily dosage of glutamic acid or its derivatives, or 5′-nucleotides (with a body weight of 60 kg) is from 0.01 g to 20 g as free glutamic acid and from 0.01 g to 20 g as free 5′-nucleotide. In the case of general adults, preferably, the daily dosage of glutamic acid or a derivative thereof, or 5′-nucleotide is 0.01 g to 20 g as free gnoretamic acid, more preferably from 0. lg to 10 g, and as a free 5, neutral age, 0.01 g to 20 g, more preferably 0.1 lg to 10 g. The daily dose can be administered once or divided into several (eg, 3) doses.

[0025] It should be noted that the composition of the present invention used in combination with the nutrients specifically includes nutrition management before and after surgery, diseases requiring intestinal cleansing, abnormal gastrointestinal conditions (suture failure, short bowel syndrome, Various types of gastrointestinal hemorrhoids), gastrointestinal tract diseases (Crohn's disease, ulcerative colitis, digestive dysfunction syndrome, hemorrhoids, protein-losing enteropathy, etc.) Used for nutritional management, elderly people with poor digestive capacity, and infants with immature digestive capacity. Further, the composition of the present invention combined with the nutrient is also used for gastrostomy and intestinal fistula patients whose gastrointestinal function is suppressed. The composition of the present invention used in combination with the nutritional agent is, for example, a patient with cerebrovascular disorder or cerebral infarction, which is a disease other than digestive organ disease, It is also suitable for administration of liquid nutrients via gastric fistula and intestinal fistula for patients who are difficult to ingest, such as dementia patients. The composition of the present invention is particularly preferably used for elderly people who have reduced digestive ability. Even more preferably, it is preferably used for patients with gastrostoma and intestinal fistula.

[0026] When the composition of the present invention contains glutamic acid or a derivative thereof, or a nutrient source other than 5'-nucleotide, the composition has a calorie of 0.5 to 3. Okcal / g, preferably 1. It is preferable that the concentration is adjusted to about 0 to 2.2 kcal / g.

[0027] When a high-viscosity composition such as a high-viscosity aqueous solution and / or a high-viscosity nutrient is used in humans, it may stay in the digestive tract and develop constipation due to its viscosity. However, it is necessary to improve the bowel movement in case of power. In addition, some of the administered nutrients may flow back to the gastroesophageal tract depending on the patient. In this case, the viscosity of the composition of the present invention is preferably a viscosity at 25 ° C. (from 400 to; 10,000 mPa-s, more preferably from 1,000 to 10, OOO mPa's.) Can be achieved by methods commonly used by those skilled in the art (eg, thickener (carboxymethylcellulose)), and even when a composition such as a nutrient is used in combination with the present composition, 25. Strength preferably 400 to; 10,000 mPa-s, more preferably 1, 00 0-10, OOOmPa.s, achieved by methods commonly used by those skilled in the art (eg, thickener (carboxymethyl cellulose)) The viscosity is a value measured with a B-type viscometer (manufactured by Toki Sangyo Co., Ltd.) under the condition of 25 ° C. Derivatives or 5'-nucleotides may be combined with the high viscosity Ku, or it may separately be formulated.

[0028] Furthermore, the composition of the present invention can be easily used in the form of food. The food of the present invention contains glutamic acid and its derivatives, and at least one selected from the group consisting of 5′-nucleotides, and is taken for a specific purpose of “improvement of bowel movement”. Moreover, the food of the present invention may be a general food including so-called health food. Furthermore, the food of the present invention can be used as a health functional food, a food for specified health use, a nutritional functional food, or a dietary supplement (nutritional supplement) as defined in the Health Functional Food System of the Ministry of Health, Labor and Welfare. Monkey. [0029] In addition, the food of the present invention may be ingested as it is, but in order to make it easier to ingest, ordinary food materials, seasonings, flavors and the like are added to the composition. It may be processed and ingested into a form such as a drink, gum, powder, tablet, granule, or jelly. In this case, for example, a tablet comprising the composition and a disintegrant, a mixture of the composition and a bulking agent (protein hydrolyzate, starch, casein, glucose, etc.), and the composition capable of sustained release in the oral cavity. A mixture of the composition with a sticky agent (gum, sublingual tablet, and troche), a solution of the composition and a solvent in which it is dissolved (eg edible oils, ethanol or water), W / O containing the composition Alternatively, an O / W emulsion, a mixture of the composition and a nutrient (eg, protein, amino acid, vitamin, lipid, glucose, etc.) can be used.

[0030] When the food of the present invention is used for the above-mentioned specific purposes, the daily intake of glutamic acid or a derivative thereof, or 5'-nucleotide, for adults (with a body weight of 60kg) or 5'-nucleotide is free gnoretamic acid. 0; 0 to 20 g, preferably 0 · Olg ·; more preferably than O · g, more preferably 0 · lg ·; 10 g. In addition, as free 5, 1 nucleotide, 0.01 g to 20 g is preferable, 0 · Olg to 10 kg is more preferable, 0 to 1 g is more preferable. On the other hand, the content of the onset glutamic acid or a derivative light in food or 5'-nucleotides, are as free Gunoretamin acid is usually 0.5 05-2. 0 wt ^_0/0, preferably from 0.1 to 1. 8% by weight, usually as free 5′-nucleotide, 0.05-2.0% by weight, preferably 0.;! ~ 1.8% by weight. By setting the content of glutamic acid or a derivative thereof or 5′-nucleotide in the above general food within the above range, the effect of improving bowel movement can be remarkably exhibited.

[0031] In the present invention, a composition for improving bowel movements comprising at least one member selected from the group consisting of glutamic acid and derivatives thereof, and 5'-nucleotides can be used for improving bowel movements. Also included are commercial packages that contain statements stating that they should be used. The package applies to both medicine and food.

[0032] The contents of all publications, including patents and patent application specifications cited in this specification, are hereby incorporated by reference herein to the same extent as if all were explicitly stated. It is built in. Hereinafter, the present invention will be specifically described with reference to examples. However, the present invention is not limited to the examples shown below.

Example

[Example 1]

The mixing ratio of each raw material is as shown in Table 1. The preparation method when 4000g is charged is described below. 1420 g of prepared water was weighed in a 5 L stainless steel bucket (hereinafter referred to as “A”) and heated to 70-80 ° C. in a hot water bath. Next, dextrin, granulated sugar, ferrous sodium citrate, sodium phosphate, phosphoric acid under high-speed stirring conditions of 3000 rpm with a high-speed stirrer (product name “TK Robomix”, Special Machine Engineering Co., Ltd.) Potassium, tripotassium citrate, and sodium dalconate were dissolved in this order. Next, a solution obtained by mixing and dissolving edible fats and oils and an emulsifier at 70 to 80 ° C. was added to A. Next, milk protein source materials (Fontera, DMV), sodium glutamate, mineral yeast mix, and flavor were sequentially added and mixed to obtain a uniform dissolved and dispersed state. Further, a solution prepared by dissolving water-soluble dietary fiber, calcium lactate, and magnesium chloride in 330 g of the prepared water was gradually added to A over about 2 minutes. Next, Vitamin Mix, sodium ascorbate and sodium erythorbate were added to A and dispersed and dissolved. The weight of A was measured, and dissolved and dispersed to 4000 g until a uniform state was obtained. An aluminum bouch (with a stopper) was filled so that the weight per piece became 150 g, and retort sterilization was performed by a two-stage heat sterilization method of 115 ° C for 9 minutes and 126 ° C for 6 minutes.

[0035] [Table 1]

• Mixing ratio of raw materials' Vitamin Mix composition

(Example 2)

The mixing ratio of each raw material is as shown in Table 2. The preparation method when 4000g is charged is described below. 1600 g of prepared water was weighed in a 5 L stainless steel bucket (hereinafter referred to as “B”) and heated to 70-80 ° C. in a hot water bath. Next, dextrin, granulated sugar, water-soluble dietary fiber, ferrous sodium citrate, zinc dalconate under high-speed stirring conditions of 2000 rpm with a high-speed stirrer (product name “TK Robomix”, Tokushu Kika Kogyo Co., Ltd.) , Copper dalconate, sodium phosphate, potassium phosphate, tripotassium citrate, sodium dalconate, and sodium chloride were dissolved in this order. Next, a solution obtained by mixing and dissolving edible fats and oils and an emulsifier at 70 to 80 ° C. was added to B. Next, milk protein source materials (Fontera, DMV), sodium glutamate, sodium inosinate, and flavor were sequentially added and mixed to obtain a uniform dissolved and dispersed state. Separately, powder agar was added to 370 g of the prepared water and swollen sufficiently, and then heated to 85 ° C to prepare a solution in which the agar was dissolved. To this, calcium lactate and magnesium chloride dissolved were gradually added to B over about 2 minutes. Next, sodium ascorbate and sodium erythorbate were added to B and dispersed and dissolved. The weight of B was measured, and it was dissolved and dispersed in 4 OOOg until it became uniform after measuring up. Two-stage heat sterilization method of 115 ° C for 9 minutes and 126 ° C for 7 minutes The retort sterilization process by was performed.

[Table 2]

- of

(Example 3)

The blending ratio of each raw material is as shown in Table 3. The preparation method when 4000g is charged is described below. 1630 g of prepared water was weighed in a 5 L stainless steel bucket (hereinafter referred to as C) and heated to about 85 ° C in a hot water bath. Next, powder agar was added and dissolved. Next, using a high-speed stirrer (product name “TK Robomix”, Special Machine Industry Co., Ltd.), under high-speed stirring conditions of 2000 rpm, dextrin, water-soluble dietary fiber, sodium ferrous citrate, zinc dalconate, Copper ruconate, sodium metaphosphate, sodium phosphate, potassium phosphate, tripotassium citrate, sodium dalconate, and sodium chloride were dissolved in order. Next, a solution obtained by mixing and dissolving edible fats and emulsifiers at 70-80 ° C was added to C. Subsequently, milk protein source material (Fontera), sodium glutamate, and flavor were sequentially added and mixed to obtain a uniform dissolved and dispersed state. Separately, a solution of calcium lactate and magnesium chloride dissolved in 260 g of prepared water was gradually added to C over about 2 minutes. Then sodium ascorbate, And sodium erythorbate was added to C and dispersed and dissolved. The weight of C was measured, and it was dissolved and dispersed in 4 OOOg until it became uniform after messing up. An aluminum bouch was filled to a weight of 150 g, and retort sterilization was performed by a two-stage heat sterilization method of 115 ° C for 9 minutes and 126 ° C for 7 minutes.

[Table 3]

-Ratio of ingredients

(Test Example 1)

In order to examine the effect of the product of the present invention prepared in Example 1 on constipation, the following experiment was conducted.

A 5-week-old male SD rat was fasted overnight, and a stomach fistula was surgically created. The stomach was fixed to the abdominal wall to suppress gastrointestinal motility. On the next day, the product of the present invention and the composition A (comparative example product) containing only MSG (sodium glutamate) were administered (6 kcal / hour), and the defecation status was determined every hour. Observed until 4 hours later.

As a result, the stool characteristics of both groups were normal stool or soft stool, and diarrhea was not observed. In addition, the proportion of defecation accumulated for each individual from the 1st to the 4th hour is 8/20 (40%) of the product of the present invention and 3/24 (12.5%) of the composition A: the product of the present invention. Compared to Composition A, significantly more defecation was observed (p <0.05, Fisher's direct probability method, Figure 1). [0041] (Test Example 2)

In order to examine the optimum viscosity of the product of the present invention prepared in Example 1, the following experiment was conducted.

A thickener (carboxymethylcellulose) was appropriately added to the product of the present invention to prepare a composition having a viscosity value of 2,000 mPa-s, 10,000 mPa-s, or 20, OOOmPa's, respectively. A gastrostomy was prepared in 6-week-old SD male rats, and the stomach was fixed to the abdominal wall to suppress gastrointestinal motility. 9 days after surgery for gastrostoma Each composition was administered 7 times every 1 hour (2.7 mL / 3g / 6k _C aV times) in the stomach, and the defecation status was completed once every hour until 1 hour I observed it.

As a result, in all individuals, stool characteristics were normal or soft, and diarrhea was an unobserved force. In addition, the percentage of individuals who defecate during the measurement period was 2,000 mPa's: 7/9 (77.8%), 10,000 mPa-s: 6/9 (66.6%), 20,000 mPa- s: 3/9 animals (33. 3%), and the composition of 2, OOOmPa's and 10, OOOmPa's had a higher percentage of individuals who defecate significantly than the composition of 20, OOOmPa's ( Figure 2). On the other hand, there was no difference in the water intake between the groups, and there was no possibility that the water intake affected the defecation!

Industrial applicability

[0042] According to the present invention, a composition having an effect on prevention or improvement of abnormal bowel movement is provided. Since the composition contains at least one member selected from the group consisting of glutamic acid and derivatives thereof, and 5′-nucleotides as an active ingredient, it has very little adverse reaction. In particular, it has the advantage that it does not cause rapid constipation, abdominal pain, diarrhea, etc. as seen when taking laxatives.

This application is based on Japanese Patent Application No. 2006-196212 filed in Japan (filing date: July 18, 2006), the contents of which are incorporated in full herein.

Claims

The scope of the claims

[I] A composition for improving bowel movement, comprising at least one member selected from the group consisting of glutamic acid and derivatives thereof, and 5′-nucleotide.

[2] The composition according to claim 1, wherein the content of glutamic acid, a derivative thereof, or 5, 1 nucleotide is 0.05 to 2.0% by weight as free glutamic acid or free 5′-nucleotide.

[3] The viscosity at 25 ° C is in the range of 400 mPa's to 10, OOOmPa's, or

2. The composition according to 2.

[4] The composition according to any one of claims 1 to 3, which is used in combination with a nutrient.

[5] The composition according to any one of claims 1 to 3, which is used in combination with a nutrient.

6. The composition according to claim 4 or 5, wherein the nutrient is a transesophageal, gastric or enteral nutrient

Yes

[7] Viscosity at 25 ° C S400mPa's ~; 10, The composition according to any one of claims 1 to 3, which is used in combination with a high viscosity composition in the range of OOOmPa's .

[8] The composition according to any one of claims 1 to 3, for use in combination with a high-viscosity composition in the range of 10,400 mPa's;

[9] The composition according to any one of claims 8 to 8, which is a pharmaceutical product.

[10] The composition according to any one of claims 1 to 8, which is a food or drink.

[II] Glutamic acid, derivatives thereof or 5′-nucleotide dosage power S, per day as free glutamic acid or free 5′-nucleotide, 0.0;! To 20 g, according to claim 9 or claim 10 Composition.

[12] The composition according to claim 10, wherein the food or drink is a health functional food or a dietary supplement.

[13] The composition according to claim 12, wherein the functional health food is food for specified health use or functional food for nutrition.

[14] It is characterized in that it contains at least one member selected from the group consisting of glutamic acid and its derivatives, and 5'-nucleotide, and has an effect of improving bowel movement, and is used for improving bowel movement Food with a label.

[15] The food according to claim 14, wherein the food is a health functional food or a dietary supplement. Yes

[16] The food according to claim 15, wherein the functional health food is a food for specified health use or a functional food for nutrition

P

P o

[17] A method for preventing or ameliorating abnormal bowel movements, comprising containing at least one member selected from the group consisting of glutamic acid and derivatives thereof, and 5′-nucleotide as an active ingredient, and administering an effective amount thereof to a subject.

[18] The effective amount of the active ingredient is 0. 05 as free glutamic acid or free 5′-nucleotide.

The method of claim 17, wherein it is ˜2.0% by weight.

19. The method according to claim 17 or 18, wherein the active ingredient is administered as a composition having a viscosity in the range of 400 mPa's to 10, OOOmPa's.

[20] The method according to any one of [17] to [19], wherein the active ingredient is administered in combination with a nutrient.

21. The method according to claim 20, wherein the nutrient is a transesophageal, gastric or enteral nutrient.

[22] The active ingredient and a composition having a viscosity in the range of 400 mPa's to 10 and OOOmPa's at 25 ° C are used in combination. The method described.

[23] Use of at least one active ingredient selected from the group consisting of glutamic acid and derivatives thereof, and 5′-nucleotide for the production of a composition for improving bowel movement.

24. The use according to claim 23, wherein the content of glutamic acid, a derivative thereof or 5′-nucleotide in the composition for improving bowel movement is 0.05-2.0% by weight as free glutamic acid or free 5′-nucleotide.

[25] The viscosity of the composition for improving bowel movement is in the range of 400 mPa's to 10, OOOmPa's.

Use as described in 23 or 24.

[26] The use according to any one of [23] or [24], wherein glutamic acid, a derivative thereof or 5′-nucleotide and a nutrient are used in combination.

[27] The use according to any one of claims 23 and 24, wherein the composition for improving bowel movement is used in combination with a nutrient.

[28] Use according to claim 26 or 27, wherein the nutrient is a transesophageal, gastric or enteral nutrient.

[29] The composition for improving bowel movements is used in combination with a high-viscosity composition having a viscosity in the range of 400 mPa's to 10, OOOmPa's at 25 ° C. Use as described in.

[30] A commercial package containing glutamic acid and a derivative thereof, and a content including at least one selected from the group consisting of 5′-nucleotides, and a description describing the use for use in improving bowel movement.

[31] The commercial package of claim 30, which relates to a medicament.

[32] The commercial package of claim 30, which relates to food.